SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Life Sciences inches up on the BSE

21 Dec 2023 Evaluate

Glenmark Life Sciences is currently trading at Rs. 632.90, up by 1.70 points or 0.27% from its previous closing of Rs. 631.20 on the BSE.

The scrip opened at Rs. 628.50 and has touched a high and low of Rs. 637.50 and Rs. 627.25 respectively. So far 465 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 675.00 on 16-Oct-2023 and a 52 week low of Rs. 369.00 on 22-Feb-2023.

Last one week high and low of the scrip stood at Rs. 658.90 and Rs. 627.25 respectively. The current market cap of the company is Rs. 7733.92 crore.

The promoters holding in the company stood at 82.85%, while Institutions and Non-Institutions held 5.02% and 12.12% respectively.

The Competition Commission of India (CCI) has given approval for Nirma’s acquisition of majority shareholding in Glenmark Life Sciences. In September this year, Glenmark Pharmaceuticals’ board had approved to divest 75 per cent stake in its subsidiary Glenmark Life Sciences to Nirma for Rs 5,651.5 crore.

Ahmedabad-based Nirma is known for its detergents, soap, and dishwashing bars. It is also into the manufacturing of industrial products like soda ash, linear alkyl benzene, alfa olefin sulphonates, fatty acid, glycerine, and sulphuric acid. 

Glenmark Life Sciences is in the business of making high-quality drugs by unlocking the possibilities of science.


Alivus Life Sciences Share Price

1062.55 -4.10 (-0.38%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×